Compare DexCom, Inc. (DXCM) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Petróleo Brasileiro SA — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Petróleo Brasileiro SA trades at $25.3 (market cap $151.94B). The key difference: Petróleo Brasileiro SA is far larger — about 4.8× DexCom, Inc.'s market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Petróleo Brasileiro SA for 25 Days on average.
| DXCM | PBR | |
|---|---|---|
Market Cap | $31.86B | $151.94B |
Volume | 3,607,070 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $92.34 | $25.30 |
52-Week Low | $54.84 | $11.54 |
Typical Hold Time | 62 Days | 25 Days |
Enterprise Value | $31.32B | $212.36B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Petrobras (PBR) trades at $24.69, up 2.92% with strong bullish momentum. The stock shows robust fundamentals with a low P/E of 6.24, ROE of 30.77%, and consistent earnings beats. Recent developments include new oil discoveries and LNG supply agreements, while technical indicators show overbought conditions with RSI above 80. Analyst consensus leans bullish with 50% buy ratings.
PBR offers compelling value with strong profitability and growth prospects, though elevated RSI suggests near-term consolidation risk. The company's expansion projects and dividend policy support long-term upside, but investors should monitor oil price volatility and Brazilian political factors that could impact operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
